2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife data
2019
Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer
Clark M, Al houssan L, Liu Z, Bernardini M. Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer. Gynecologic Oncology 2019, 154: 261. DOI: 10.1016/j.ygyno.2019.04.603.Peer-Reviewed Original Research
2018
Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection
Lee Y, Lee J, Paik E, Clark M, Kim R, Brown T, May T. Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection. Gynecologic Oncology 2018, 149: 98. DOI: 10.1016/j.ygyno.2018.04.226.Peer-Reviewed Original Research